Swiss National Bank’s Inhibrx INBX Stock Holding History

Swiss National Bank’s Portfolio INBX Stock Details INBX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.32M	Sell	13,900 -500	-3%	-$50.1K	﹤0.01%	2124
2026 Q1	$968K	Buy	+14,400	New	+$1.07M	﹤0.01%	2169

Other funds holding INBX

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

HighTower Advisors Chicago, Illinois $104B AUM 28.3% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Swiss National Bank's INBX Position: Q2 2026 in Review

Swiss National Bank reduced its Inhibrx (INBX) stake by 3.5% in Q2 2026, selling an estimated $50.1K and leaving 13,900 shares worth $1.32M. The position accounts for ﹤0.01% of the portfolio, ranked #2124.

Swiss National Bank first reported a position in INBX in Q1 2026 and has held it in 2 quarters since. 162 funds tracked by Wall St. Rank hold INBX as of Q2 2026.

Swiss National Bank held 13,900 shares of Inhibrx worth $1.32M as of Q2 2026.
Swiss National Bank sold 500 Inhibrx shares in Q2 2026, an estimated $50.1K.
Inhibrx made up ﹤0.01% of Swiss National Bank's portfolio in Q2 2026, its #2124 holding.
Swiss National Bank first reported a position in Inhibrx in Q1 2026 and has held it in 2 quarters since.
162 funds tracked by Wall St. Rank held Inhibrx as of Q2 2026.

Based on Swiss National Bank's 13F filing for Q2 2026, filed 11 Aug 2026.